Leadership

  • Regent Laporte, DVM, MSc, PhD – Program Director
  • Claudio D. Schteingart, PhD
  • Maria Paz Rodriguez, DDS, MS, MAS – Communication Director

General Administration

  • Robert Houghtaling, BA – Program Manager
  • Tiana Mack-Miller, BS – Communication Assistant

Faculty

CLRE-236 Translational Research Fundamentals

  • Regent Laporte, DVM, MSc, PhD – Course Director
  • Maria Paz Rodriguez, DDS, MS, MAS – Course Co-Director
  • Roberta V. Alexander, PharmD, PhD
  • Andrew Baker, BEng (Hons)
  • Elizabeth Brunk, PhD
  • Timothy R. Geiger, PhD
  • Mark S. Hixon, PhD
  • Kanthi A. Kollengode, MD, MAS
  • Amit Kumar, PhD
  • Patrick McConville, PhD
  • Pierre Riviere, PhD
  • Marina Seme Nelson, PhD

CLRE-237 Translational Regenerative Medicine

  • Sheldon Morris, MD, MPH – Course Director
  • Catriona Jamieson, MD, PhD – Course Co-Director
  • Eric Ahrens, PhD
  • Michael Choi, MD
  • Joseph D. Ciacci, MD
  • Scott M. Lippman, MD
  • Martin Marsala, MD
  • Jeremy Pettus, MD
  • Jeremy Rich, MD, MHS, MBA
  • Vickie Sheckler
  • Robert Signer, PhD
  • Tiffany Tanaka, MD
  • Holly Young, MSc

CLRE-238 Applied Translational Research

  • Regent Laporte, DVM, MSc, PhD – Course Director
  • Claudio D. Schteingart, PhD – Course Co-Director
  • Maria Paz Rodriguez, DDS, MS, MAS – Course Manager
  • Thomas Bicsak, PhD
  • Michael Okay. Dunn, PhD, MBA
  • Mark Fineman, MAS, MS, PhD
  • Wolfgang Glaesner, PhD
  • David G. Parkes, PhD

CLRE-239 Applied Translational Research II

  • Regent Laporte, DVM, MSc, PhD – Course Director
  • Claudio D. Schteingart, PhD – Course Co-Director
  • Maria Paz Rodriguez, DDS, MS, MAS – Course Manager
  • Steven L. Bender, PhD
  • Cristian Rodriguez, MD
  • Jury Panel for Final Presentations
  • Mark Fineman, MAS, MS, PhD
  • Mark S. Hixon, PhD
  • Kanthi A. Kollengode, MD, MAS

CLRE-40004 Capstone Project

  • Maria Paz Rodriguez, DDS, MS, MAS – Course Director
  • John M. York, PharmD, MBA – Course Co-Director​


Eric Ahrens, PhD

Roberta V. Alexander, PharmD, PhD
Dr. Roberta Alexander has over 20 years of pharmaceutical and diagnostics business expertise throughout a number of therapeutic areas together with rheumatology, gastroenterology, ache, endocrinology, irritation, and cardiovascular ailments. She has a novel background encompassing medical and preclinical analysis. Currently, Dr. Alexander serves as Senior Director of Clinical Research & Medical Affairs at Exagen, a diagnostics firm, the place she oversees medical analysis and enterprise improvement.
Dr. Alexander obtained her PharmD diploma and her PhD in Molecular Pharmacology from the Università degli Studi di Perugia, Italy. She then accomplished a Postdoctoral Fellowship in Molecular Pharmacology on the School of Medicine of the University of Pennsylvania.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Alexander teaches about diagnostics within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program. 

Andrew Baker, BEng (Hons)

Mr. Andrew Baker is a medical expertise business professional with over 30 years of expertise. A graduate of the University of Portsmouth, he has managed industrial and medical options at Maxim Integrated for over 11 years. Currently, as Managing Director of the Industrial & Healthcare Business Unit, Mr. Baker is main a staff of engineers targeted on growing options for Wearable Health, specializing in energy administration and sensing applied sciences. Mr. Baker acquired his BEng (Hons) in Electrical Engineering from the University of Portsmouth. At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Mr. Baker teaches about medical expertise within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.

Steve L. Bender, PhD
Dr. Steve Bender has over 25 years of drug discovery expertise primarily targeted on Oncology and, extra just lately, in Immuno-Oncology, and spanning each small molecule and biotherapeutic approaches.  At the Genomics Institute of the Novartis Research Foundation (GNF), he led a gaggle of roughly 60 most cancers biologists and immunologists because the Executive Director of Cancer Therapeutics. During his tenure, the Cancer Therapeutics groups found six novel drug candidates which have progressed into medical trials. He is now Entrepreneur in Residence at Boxer Capital, in addition to Founder and Principal Consultant at NexTx Insights.
Dr. Bender acquired his BS in Chemistry from the University of Illinois Urbana-Champaign and his PhD in Organix Chemistry from Harvard University.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Bender mentors a scholar staff in a drug case research within the Applied Translational Research II (CLRE-239) course within the Translational Science Certificate Program.

Thomas Bicsack, PhD
Dr. Thomas Bicsak is a regulatory affairs skilled with almost 30 years of expertise in all phases of drug improvement. He is at the moment Vice President of Regulatory Affairs and Quality at Biosplice Therapeutics (beforehand often known as Samumed), overseeing regulatory technique for all improvement packages. Earlier, Dr. Bicsak was Senior Vice President of Regulatory Affairs and Quality Assurance at Elcelyx Therapeutics, main the regulatory technique for the event of a novel remedy for kind 2 diabetes in sufferers with renal impairment.

Dr. Bicsak acquired his BA (Hons) in Biochemistry from Rutgers University and his PhD in Chemistry from the University of California, San Diego, the place he then accomplished a Postdoctoral Fellowship in Reproductive Endocrinology on the School of Medicine.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Bicsak teaches about regulatory affairs within the Applied Translational Research (CLRE-238) course within the Translational Science Certificate Program.
 
Elizabeth C. Brunk, PhD
Dr. Elizabeth Brunk is an skilled tutorial computational scientist who’s a advisor for the pharmaceutical business. She is at the moment an Assistant Professor on the Department of Pharmacology and the Department of Chemistry of the University of North Carolina, the place she can also be a college of the Integrative Program for Biological & Genome Sciences, the Lineberger Cancer Center, and the Computational Medicine Program. Dr. Brunk’s analysis focuses on the identification of functionally related variants in most cancers, the understanding of how molecular pathways and variants drive drug response, the event of strategies to combine most cancers omics knowledge throughout organic scales, and the event of instruments for purposeful/precision drugs.
Dr, Brunk acquired her BS in Biochemistry from the University of Michigan, her MSc in Chemistry and Molecular Modeling of Biomolecular Systems collectively from the University of Amsterdam, The Netherlands, and the École normale supérieure de Lyon, France, and her PhD in Computational Chemistry from the École Polytechnique Fédérale de Lausanne, Switzerland. She then accomplished a Postdoctoral Research Fellowship supplied collectively by the University of California, Berkeley, and the Joint BioEnergy Institute of the US Department of Energy.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Brunk teaches about purposeful/precision drugs within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.
 
Michael Choi, MD
 
Joseph D. Ciacci, MD

Michael K. Dunn, PhD, MBA
Dr. Michael Dunn is an mental property and scientific intelligence skilled with over 20 years of pharmaceutical business expertise. He is at the moment Senior Director of Scientific Information & Intelligence on the Ferring Research Institute and a member of Ferring Pharmaceuticals’ Global Patent Department.  His duties embrace patent technique and prosecution for drug discovery tasks, scientific aggressive intelligence, and analysis reporting. Dr. Dunn has notably printed on the impression of patent timing on pharmaceutical product exclusivity, on peptide therapeutics, and on knowledge integrity in analysis environments.
Dr. Dunn acquired his PhD in Biological Chemistry & Molecular Pharmacology from Harvard Medical School and his MBA from the Johnson Graduate School of Management of Cornell University. He can also be an authorized Patent Agent.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Dunn teaches about innovation and mental property within the Applied Translational Research (CLRE-238) course within the Translational Science Certificate Program.
 
Mark Fineman, MAS, MS, PhD
Dr. Mark Fineman is a seasoned pharmaceutical government with over 30 years of expertise main R&D for each private and non-private firms. In these roles, he has led the technique and execution of a number of packages starting from early discovery by world commercialization of a number of first-in-class merchandise. He is at the moment Senior Vice President of Clinical Affairs at Biosplice Therapeutics overseeing all musculoskeletal and neurodegenerative medical packages. Dr. Fineman can also be the Program Development Leader for lorecivivint, a first-in-class drug candidate in Phase 3 medical trials for the remedy of knee osteoarthritis.
Dr. Fineman acquired his Master of Advanced Studies in Clinical Research and his MS in Molecular Pathology from the University of California, San Diego, and his PhD in Medicine from the Vrije Universiteit Amsterdam, The Netherlands.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Fineman teaches a drug case research within the Applied Translational Research (CLRE-238) course within the Translational Science Certificate Program.
 
Timothy Geiger, PhD
Dr. Timothy Geiger has over 20 years of expertise within the biotechnology and pharmaceutical industries. He is at the moment Senior Manager of Field Application Scientists for the Southwest Business Unit at ProteinEasy, a subsidiary of Bio-Techne Corp., a biotechnology and medical diagnostic holding firm. Before getting concerned within the biotechnology business, Dr. Geiger was a Scientist at Allergan, a pharmaceutical firm, the place he was overseeing a staff of analysts growing molecular biology and immune-based analytical strategies for drug improvement.
Dr. Geiger acquired his PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Geiger teaches about omics instruments within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.
 
Wolfgang Glaesner, PhD
Dr. Wolfgang Glaesner is a protein biochemist with over 20 years of expertise within the discovery and improvement of peptide, protein, and antibody therapeutics. He is at the moment the Chief Scientific Officer of Biotechnology Research & Development on the Lilly Biotechnology Center in San Diego, part of the pharmaceutical firm Eli Lilly. In this position, Dr. Glaesner focuses on the invention and engineering of peptides and antibodies throughout all therapeutic areas, in addition to the event of novel molecular codecs, comparable to bi-specific antibodies, fusion antibodies, and antibody-drug conjugates. Notably, he led the invention staff that designed dulaglutide (TRULICITY), a best-in-class drug within the kind 2 diabetes area.
Dr. Glaesner acquired his PhD in Biochemistry from the University of Göttingen, Germany, and accomplished a Postdoctoral Fellowship in Protein Chemistry on the pharmaceutical firm Novartis, Basel, Switzerland.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Glaesner teaches about biologics within the Applied Translational Research (CLRE-238) course within the Translational Science Certificate Program.
 
Mark S. Hixon, PhD 
Dr. Mark Hixon is an revolutionary and multidisciplinary pharmaceutical business skilled with a profitable file in drug improvement and over 20 years of expertise. He is at the moment Senior Director of Modeling and Simulation at VeriSIM Life, a contract analysis group, the place he focuses on mission strategic steering and constructing translational bridges of medical relevance. Earlier in his profession, Dr. Hixon spent 14 years at Takeda Pharmaceuticals, the place he notably led modeling and simulation efforts to make seminal contributions to a number of drug discovery and improvement mission groups.
Dr. Hixon acquired his PhD in Medicinal Chemistry from the University of Kansas.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Hixon teaches about medical improvement within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.
 
Robert Houghtaling, BA – Program Manager
 
Catriona Jamieson, MD, PhD – Course Co-Director
 
Kanthi A. Kollengode, MD, MAS 
Dr. Kanthi Kollengode is at the moment Associate Medical Director for Clinical Development on the pharmaceutical firm Bristol-Myers Squibb, the place she can also be Lead Physician for Ozanimod for Crohn’s Disease, which is in Phase 3 medical trials. She acquired her MD diploma from the Rajiv Gandhi University of Health Sciences in Bangalore, India, the place she targeted on well being schooling and outreach whereas working in free clinics and organizing well being schooling and prevention packages for faculties. Dr. Kollengode then accomplished a Clinical Research Fellowship in Hematology/Oncology on the University of Southern California and obtained her Master of Advanced Studies in Clinical Research on the University of California, San Diego.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Kollengode teaches about biomarkers and diagnostics within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.
 
Amit Kumar, PhD
Dr. Amit Kumar is an completed serial entrepreneur, investor, and innovator within the biotechnology area. He at the moment serves because the Chief Executive Officer, Chairman, and President of Anixa Biosciences, a biotechnology firm targeted on growing immunotherapies and vaccines in oncology and infectious ailments. Dr. Kumar can also be a member of the American Cancer Society Boof Directors. 
Dr. Kumar graduated from Occidental College with a BS in Chemistry and obtained his PhD in Physical Chemistry from the California Institute of Technology, and accomplished a Postdoctoral Fellowship in Chemistry at Harvard University.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Kumar teaches about cell & gene remedy within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.
 
Regent Laporte, DVM, MSc, PhD
Dr. Regent Laporte is a scientific chief in Translational Pharmacology with over 20 years of expertise within the biotechnology and pharmaceutical business throughout a number of therapeutic areas, together with Emergency and Critical Care Medicine, Hepatology, Gastroenterology, Urology, and Reproductive Health. He is Founder and Principal Consultant at Laporte & Associates, a biotechnology and pharmaceutical R&D consulting firm, and Senior Director of Translational Pharmacology at Peptide Logic, a biopharmaceutical startup firm combining some great benefits of artificial peptides and recombinant antibodies to create revolutionary semi-synthetic biologics for the remedy of ache and different pathological circumstances in choose therapeutic areas. Previously, he was Director of Exploratory Pharmacology at Ferring Pharmaceuticals. 
Dr. Laporte acquired his Doctorate of Veterinary Medicine and his Master of Science in Veterinary Anatomy and Physiology from the Université de Montréal, Canada. He acquired his PhD in Pharmacology from the University of Vermont College of Medicine and accomplished post-doctoral research in Cardiology and in Obstetrics, Gynecology, and Reproductive Biology at Harvard Medical School.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Laporte is Program Director of the Translational Science Certificate, Module Director of the Concentration in Translational Science of the Master of Advanced Studies in Clinical Research, and Course Director of Translational Research Fundamentals (CLRE-236), Applied Translational Research (CLRE-238), and Applied Translational Research II (CLRE-239).
 
Scott M. Lippman, MD
 
Tiana Mack-Miller, BS – Communication Assistant
 
Martin Marsala, MD
 
Patrick McConville, PhD
Dr. Patrick McConville has intensive information in translational imaging, with over 20 years of business expertise in preclinical imaging for drug discovery and improvement functions, comparable to magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), bioluminescence, fluorescence, and 2-dimensional X-ray. He is at the moment Vice President of the contract analysis group inviCRO, which launched the primary multi-modality imaging heart in San Diego. In addition, he additionally serves as Professor of Practice in Radiology on the School of Medicine of the University of California San Diego the place he focuses on industrial multi-modality translational and discovery imaging. Previously, Dr. McConville was a Co-Founder and the Chief Scientific Officer at Molecular Imaging Inc., a contract analysis group that established the primary multi-modality CRO imaging heart in Ann Arbor, Michigan.
Dr. McConville acquired his BSc (Hons) in Physica and Computer Science from the University of New South Wales, Australia, and his PhD in Medical Physics from the Queensland University of Technology, Australia.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. McConville teaches about translational imaging within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.

Sheldon Morris, MD, MPH – Course Director
 
David G. Parkes, PhD
Dr. David Parkes has over 25 years of pharmaceutical business expertise in drug discovery and improvement throughout a number of therapeutic areas, together with diabetes, weight problems, non-alcoholic fatty liver illness and steatohepatitis (NAFLD/NASH), and cardiovascular ailments. He is at the moment Chief Scientific Officer at Abvance Therapeutics, a pharmaceutical firm targeted on diabetes, in addition to scientific advisor for different pharmaceutical firms, together with Astra Zeneca, Gilead, Prosciento, Fractyl, and Prolynx. Earlier, he performed pivotal management roles at Amylin Pharmaceuticals within the discovery and improvement of exenatide (BYETTA, BYDUREON), pramlintide (SYMLIN), and metreleptin (MYALEPT), three first-in-class medication for the remedy of metabolic ailments.
Dr. Parkes acquired his BSc (Hons) in Pharmacology and his PhD in Pharmacology and Physiology from the University of Melbourne, Australia.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Parkes teaches a drug case research within the Applied Translational Research (CLRE-238) course within the Translational Science Certificate Program.
 
Jeremy Pettus, MD
 
Jeremy Rich, MD, MHS, MBA

Pierre Rivière, PhD
Dr. Pierre Rivière is a pharmacologist by coaching with over 25 years of expertise within the pharmaceutical business, primarily in drug discovery and early-stage improvement of peptide therapeutics. He is the Founder and at the moment Chief Executive Officer of Peptide Logic, a biopharmaceutical firm combining some great benefits of artificial peptides and recombinant antibodies to create revolutionary semi-synthetic biologics for ache and different pathological circumstances in choose therapeutic areas. Prior to that, Dr. Rivière  was Chief Scientific Officer of CovX, which was a Pfizer-owned biopharmaceutical firm, in addition to Senior Vice President of Pfizer Worldwide R&D.
Dr. Riviere acquired his PhD in Animal Physiology and Biology from the Institut National Polytechnique de Toulouse, France.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Rivière teaches about drug discovery within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.
 
Cristian Rodriguez, MD
Dr. Cristian Rodriguez has over 13 years of expertise in biopharmaceutical improvement and world medical affairs. He is at the moment Senior Director in Immunology & Fibrosis and Clinical Trial Physician for Eosinophilic Esophagitis at Bristol-Myers Squibb (BMS) in San Diego. He was beforehand Medical Director in Innovative Medicines Development in Immunosciences at BMS in New Jersey. Prior to becoming a member of the pharmaceutical business, Dr. Rodriguez was a Medical Officer within the Immune Tolerance Network on the National Institute of Allergy and Infectious Diseases (NAID, NIH), after spending a decade as a medical immunologist and allergist and attending professor on the University of Chile and Pediatric Immunology Clinic Head on the San Borja General Hospital in Santiago.
Dr. Rodriguez obtained his MD diploma and accomplished his Residency in Clinical Immunology on the University of Chile, adopted by a Fellowship in Pediatric Clinical Immunology, Allergy, and Rheumatology on the School of Medicine of the University of California, Los Angeles.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Rodriguez mentors a scholar staff in a drug case research within the Applied Translational Research II (CLRE-239) course within the Translational Science Certificate Program.
 
M. Paz Rodriguez, DDS, MS, MAS
Dr. Paz Rodriguez is an unbiased basic dentist training in Santiago, Chile. After finishing her Doctorate in Dental Surgery on the Universidad Finis Terrae in Santiago with a Minor in Communications, she obtained a Master of Science in Dental Implant Surgery and Rehabilitation from the Universidad de los Andes in Santiago. More just lately, she accomplished her Master of Advanced Studies in Clinical Research on the University of California, San Diego.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Rodriguez is Communication Director of the Translational Science Certificate, leveraging the entrepreneurial and communication experience that she has developed as a patient-experience-focused unbiased basic dentist and her curiosity within the transformative potential of translational science in healthcare. She can also be Course Director of the Certificate Capstone Project (CLRE-40004), Course Co-Director of Translational Research Fundamentals (CLRE-236), and Course Manager of Applied Translational Research (CLRE-238) and Applied Translational Research II (CLRE-239).
 
Claudio D. Schteingart, PhD
Dr. Claudio Schteingart is at the moment an unbiased advisor with over 25 years of expertise within the pharmaceutical business. He retired in 2018 as Vice President, Science & Technology – Research, at Ferring Pharmaceuticals the place he was answerable for the analysis of latest applied sciences for the invention and improvement of novel peptide therapeutics, for guiding drug discovery packages, and for supporting drug candidates in improvement. He contributed to the invention of the peptidic GnRH antagonist degarelix, launched in 2009 as FIRMAGON, and lots of different peptidic drug candidates in numerous levels of medical improvement for urology, ladies’s well being, vital care drugs, and gastroenterology.
Dr. Schteingart acquired a PhD in Chemistry from the University of Buenos Aires, Argentina. After postdoctoral research within the Department of Chemistry of the University of California, San Diego, he moved to the Department of Medicine the place he carried out analysis within the chemistry, physiology, metabolism, and physicochemical properties of biliary parts and lipids.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Schteingart is Course Co-Director of Applied Translational Research (CLRE-238) and Applied Translational Research II (CLRE-239) within the Translational Science Certificate Program.
 
Marina Seme Nelson, PhD 
Dr. Marina Seme Nelson has over 20 years of expertise within the pharmaceutical business and focuses on drug improvement and nonclinical security evaluation. She is at the moment Drug Development Leader for Early Phase Development Solutions on the contract analysis group Covance, Inc., the place she gives scientific and strategic route to drug improvement packages and product improvement. Earlier, Dr. Nelson was Study Director and Drug Safety and Metabolism Representative on the pharmaceutical firm Wyeth, the place she led multi-disciplinary and world improvement groups.
Dr. Seme Nelson acquired her MS in Biotechnology from Northwestern University and her PhD in Pharmacology and Toxicology from the Medical College of Wisconsin.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. Seme Nelson teaches about nonclinical improvement within the Translational Research Fundamentals (CLRE-236) course within the Translational Science Certificate Program.
 
Vickie Sheckler
 
Robert Signer, PhD
 
Tiffany Tanaka, MD
 
John M. York, PharmD, MBA
Dr. John York is a commercially oriented advertising and medical skilled with over 25 years within the pharmaceutical and biotechnology industries throughout multiples therapeutic areas, together with hematology/oncology, ophthalmology, cardiovascular drugs, respiratory drugs, pediatrics, dermatology, and neurology. After assuming numerous management roles on the pharmaceutical firms Bristol-Myers Squibb, Amgen, and Allergan, and on the medical communications and consulting firm HDI, he based the medical communications and consulting firm Akita Biomedical the place he’s at the moment Chief Executive Officer and Principal. He can also be Lecturer and Lead Instructor on the Rady School of Management of the University of California, San Diego.
Dr. York acquired his PharmD diploma from the University of Michigan and accomplished an business postdoctoral fellowship collectively supplied by Rutgers University, Warner-Lamber, and Parke-Davis. He then obtained an MBA diploma from Indiana University, in addition to a Life Sciences Business Certificate and a Marketing Certificate from the University of California, Berkeley.
At the Altman Clinical and Translational Research Institute of the School of Medicine of the University of California, San Diego, Dr. York is Course Co-Director of the Capstone Project (CLRE-40004) within the Translational Science Certificate Program.
 
Holly Young, MSc



Sources

Leave a Reply

Your email address will not be published. Required fields are marked *